

**SUPPLEMENTARY TABLE 1. Mean number of prescription stimulant fills among persons aged 5–64 years with at least one prescription stimulant fill, overall and by sex and age group, MarketScan Commercial Databases, United States, 2016–2021**

Sex/age group (yrs)	Mean no. of stimulant fills, by year					
	2016	2017	2018	2019	2020	2021
<b>Both sexes, all ages</b>	7.4	7.5	7.6	7.6	7.4	7.4
<b>Females (all)</b>	7.4	7.5	7.6	7.6	7.5	7.3
5–9	7.1	7.1	7.1	7.1	6.6	6.8
10–14	6.9	6.9	6.9	6.8	6.0	6.3
15–19	6.2	6.3	6.2	6.2	5.7	5.7
20–24	7.1	7.1	7.1	7.0	6.8	6.6
25–29	8.1	8.2	8.3	8.3	8.2	7.8
30–34	8.2	8.3	8.4	8.4	8.5	8.1
35–39	8.0	8.3	8.3	8.5	8.6	8.3
40–44	7.8	8.0	8.1	8.2	8.4	8.2
45–49	7.6	7.8	7.9	8.0	8.1	8.0
50–54	7.5	7.7	7.8	7.9	7.9	7.8
55–59	7.7	7.7	7.8	7.8	7.9	7.9
60–64	7.6	7.7	7.8	7.8	7.9	7.8
<b>Males (all)</b>	7.4	7.5	7.6	7.6	7.4	7.4
5–9	7.8	7.9	7.9	7.8	7.3	7.5
10–14	7.4	7.4	7.4	7.4	6.7	7.1
15–19	6.2	6.2	6.3	6.2	5.8	5.9
20–24	6.9	7.0	6.9	6.9	6.8	6.6
25–29	8.1	8.3	8.4	8.5	8.4	8.1
30–34	8.5	8.7	8.7	8.7	8.8	8.5
35–39	8.5	8.7	8.6	8.7	8.8	8.6
40–44	8.1	8.3	8.5	8.6	8.7	8.6
45–49	7.9	8.0	8.2	8.2	8.3	8.3
50–54	7.8	7.9	7.9	7.9	8.0	7.9
55–59	7.9	8.0	8.0	7.9	8.0	8.0
60–64	7.8	7.8	7.8	8.0	8.0	7.9

**SUPPLEMENTARY TABLE 2. Percentage of persons aged 5–64 years with at least one prescription stimulant fill who met claims data attention-deficit/hyperactivity disorder case definition criteria\* in preceding or current calendar year, overall and by sex and age group, MarketScan Commercial Databases, United States, 2016–2021**

Sex/age group (yrs)	Percentage, by year					
	2016	2017	2018	2019	2020	2021
<b>Both sexes, all ages</b>	76.7	72.9	72.2	72.8	73.0	73.1
<b>Females (all)</b>	73.3	69.5	68.4	68.9	69.3	70.0
5–9	86.4	84.1	86.2	86.9	86.7	86.8
10–14	84.8	82.2	83.2	84.0	83.7	84.7
15–19	77.7	74.6	74.8	75.6	75.6	76.6
20–24	75.4	70.5	68.6	68.8	69.5	70.3
25–29	74.5	69.5	68.3	68.1	68.1	69.8
30–34	73.3	69.0	66.6	67.7	68.8	68.4
35–39	71.3	66.9	65.1	65.7	66.1	66.8
40–44	68.4	64.5	62.7	62.9	64.5	65.3
45–49	66.3	62.6	60.5	61.3	62.4	63.1
50–54	63.4	60.0	58.9	59.6	60.5	61.5
55–59	60.0	57.5	56.5	57.7	58.1	58.8
60–64	56.3	54.7	53.4	55.7	56.4	57.3
<b>Males (all)</b>	79.7	75.9	75.5	76.4	76.4	76.2
5–9	87.8	85.8	87.7	88.5	88.7	88.8
10–14	87.0	84.1	85.4	86.7	86.7	87.2
15–19	80.9	77.5	78.3	79.8	80.0	80.6
20–24	76.7	71.3	70.4	71.0	71.5	71.8
25–29	76.7	71.5	69.7	70.5	70.4	70.5
30–34	77.0	72.2	69.7	70.4	70.7	70.1
35–39	75.5	70.9	68.6	69.0	69.7	69.5
40–44	72.2	68.9	66.1	67.3	67.2	67.7
45–49	70.3	66.1	64.2	64.4	65.8	66.0
50–54	67.0	62.6	61.1	61.9	63.4	64.2
55–59	62.5	59.5	58.5	59.4	60.0	61.5
60–64	58.0	55.1	54.5	57.5	57.7	59.2

**Abbreviations:** ADHD = attention deficit/hyperactivity disorder; ICD-9-CM = *International Classification of Diseases, Ninth Revision, Clinical Modification*; ICD-10-CM = *International Classification of Diseases, Tenth Revision, Clinical Modification*

\* To meet the case definition for ADHD care receipt, enrollees had to have  $\geq 2$  health care encounters with an ADHD ICD-9-CM diagnosis code of 314.X or an ICD-10-CM diagnosis code of F90 occurring  $\geq 7$  days apart, or  $\geq 1$  visit with an ADHD diagnosis code and  $\geq 2$  prescriptions for ADHD medications (amphetamine and mixed amphetamine salts, atomoxetine, clonidine, dexamethylphenidate, dextroamphetamine, guanfacine, lisdexamfetamine, methamphetamine, or methylphenidate) filled  $\geq 14$  days apart; these criteria had to be met during the preceding or current calendar year.